# Warm Autoimmune Haemolytic Anaemia Management in Asia‐Pacific: A Delphi Panel Expert Consensus and Systematic Literature Review

## TL;DR

This study reviews the management of warm autoimmune haemolytic anaemia in the Asia-Pacific region and provides expert consensus on diagnosis and treatment.

## Contribution

The paper presents a Delphi panel consensus and systematic review tailored to the Asia-Pacific region's unique challenges in wAIHA management.

## Key findings

- Corticosteroids are used in over 80% of wAIHA patients with response rates of 81%–96%.
- Restricted access to rituximab and gaps in physician awareness are key challenges in the APAC region.
- Expert consensus recommends routine screening for underlying conditions and early interventions.

## Abstract

This study aimed to assess the burden of warm autoimmune haemolytic anaemia (wAIHA) and treatment practices in the Asia‐Pacific (APAC) region.

A systematic literature review (SLR) of observational studies in adult patients with wAIHA was conducted. Based on these findings, a Delphi panel was convened to develop consensus recommendations on diagnosis, treatment goals and algorithms by subtypes, unmet needs and research priorities.

The SLR included 37 publications. Clinical guidelines consistently recommend direct antiglobulin testing for diagnosis and corticosteroids as first‐line treatment. Real‐world data showed corticosteroid use in over 80% of patients, with response rates of 81%–96%, and relapse rates of 18%–45%. The Delphi panel recommended routine screening for underlying conditions and early therapeutic interventions. Key challenges identified included restricted access to rituximab in parts of the APAC region and gaps in physician awareness. Research priorities included optimising therapy, assessing long‐term outcomes and improving disease awareness.

This research emphasises the need for evidence‐based, regionally adaptable treatment algorithms for wAIHA in the APAC region. Ongoing data gaps related to epidemiology, outcomes and quality of life must be addressed to enhance patient care.

The authors have confirmed clinical trial registration is not needed for this submission.